alexa Circulating Vascular Endothelial Growth Factor In Type 2 Diabetes Mellitus With Diabetic Nephropathy
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

12TH ANNUAL CONFERENCE ON Nephrology & Urology

Alaa A Sabry
Mansoura University, Egypt
Posters & Accepted Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959-C1-043
Mechanisms underlying the development of diabetic kidney disease are complex. Among the many potential pathogenic mechanisms responsible for the development of diabetic kidney disease, the angiogenic growth and survival factor, Vascular Endothelial Growth Factor (VEGF) has been suggested to be an important player. The aim of this study was to evaluate circulating vascular endothelial growth factor level in diabetic nephropathy and to assess whether its level is related to the severity of diabetic nephropathy in type 2 diabetic patients. 38 type 2 diabetic patients and 8 healthy subjects of matched age, sex and BMI served as a control group in the study. The studied patients were categorized into three groups according to urinary albumin excretion as follows: Group 1: Comprised of 13 normoalbumiuric (UAE <30 mg/24 h) type 2 diabetic patients; Group 2: Comprised of 12 microalbumiuric (UAE 30–299 mg/24 h) type 2 diabetic patients and; Group 3: Comprised of 13 macroalbumiuric (UAE ≥300 mg/24 h) type 2 diabetic patients. Sera were separated by centrifugation and kept frozen at (-20°C) for analysis of serum total VEGF by enzyme immunoassay (EIA) method using Accucyte® human VEGF kits supplied by Accucyte® (USA). Fundus examination, electrocardiograph and abdominal ultrasound were done. There was significant increase in serum VEGF in nephropathic group compared to non nephropathic group (7.546±3.579 versus 19.344±11.649, P=0.0001). There was significant increase in serum VEGF in macro-albuminuric subgroup compared to micro-albumiuric subgroup (26.046±11.973 versus 12.083±5.396, P=0.001). There was significant increase in serum VEGF in non nephropathic group, nephropathic group and in all patient series compared to control group (7.546±3.579, 19.344±11.649, 15.307±11.151 and 2.737±1.056 respectively). There was significant correlation between serum VEGF, UAE (P=0.69, R=0.0001), (serum creatinine (P=0.45, R=0.024). The results of the present study on a quiet homogeneous group of diabetics with regard to age, sex, BMI clarified that VEGF may be a good index for early detection and determination of the severity of diabetic nephropathy due to type 2 diabetes.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version